Login to Your Account

Clinic Roundup

Tuesday, June 21, 2011
GTx Inc., of Memphis, Tenn., initiated a Phase IIb trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot (leuprolide acetate for depot suspension) for first-line treatment of advanced prostate cancer. The company said that the trial is an open-label study of 156 men with advanced prostate cancer. The primary endpoint is the proportion of patients who achieve castration by day 60.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription